KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Operating Leases (2019 - 2025)

Historic Operating Leases for Arbutus Biopharma (ABUS) over the last 7 years, with Q3 2025 value amounting to $391000.0.

  • Arbutus Biopharma's Operating Leases fell 6002.04% to $391000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $391000.0, marking a year-over-year decrease of 6002.04%. This contributed to the annual value of $806000.0 for FY2024, which is 3998.51% down from last year.
  • As of Q3 2025, Arbutus Biopharma's Operating Leases stood at $391000.0, which was down 6002.04% from $575000.0 recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Operating Leases ranged from a high of $2.5 million in Q1 2021 and a low of $391000.0 during Q3 2025
  • Its 5-year average for Operating Leases is $1.5 million, with a median of $1.6 million in 2023.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 1367.28% in 2021, then crashed by 6002.04% in 2025.
  • Arbutus Biopharma's Operating Leases (Quarter) stood at $2.2 million in 2021, then fell by 18.65% to $1.8 million in 2022, then dropped by 26.01% to $1.3 million in 2023, then crashed by 39.99% to $806000.0 in 2024, then crashed by 51.49% to $391000.0 in 2025.
  • Its Operating Leases stands at $391000.0 for Q3 2025, versus $575000.0 for Q2 2025 and $626000.0 for Q1 2025.